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Abstract
Objectives:	The	aim	of	Working	Group	1	was	to	address	the	influence	of	different	
local	 (implant	 length,	 diameter,	 and	 design)	 and	 systemic	 (medications)	 factors	 on	
clinical,	 radiographic,	and	patient‐	reported	outcomes	 in	 implant	dentistry.	Focused	
questions	 on	 (a)	 short	 posterior	 dental	 implants	 (≤6	mm),	 (b)	 narrow	 diameter	 im‐
plants,	(c)	implant	design	(tapered	compared	to	a	non‐tapered	implant	design),	and	(d)	
medication‐	related	dental	implant	failures	were	addressed.
Materials and methods:	Four	systematic	reviews	were	prepared	in	advance	of	the	
Consensus	 Conference	 and	were	 discussed	 among	 the	 participants	 of	 Group	 1.	
Consensus	statements,	clinical	recommendations,	and	recommendations	for	future	
research	were	based	on	structured	group	discussions	until	consensus	was	reached	
among	 the	 entire	 expert	Group	1.	 The	 statements	were	 then	presented	 and	 ac‐
cepted	following	further	discussion	and	modifications	as	required	by	the	plenary.
Results:	Short	implants	(≤6	mm)	revealed	a	survival	rate	ranging	from	86.7%	to	100%,	
whereas	standard	implant	survival	rate	ranged	from	95%	to	100%	with	a	follow‐	up	from	
1	to	5	years.	Short	implants	demonstrated	a	higher	variability	and	a	higher	Risk	Ratio	
[RR:	1.24	(95%	CI:	0.63,	2.44,	p	=	0.54)]	for	failure	compared	to	standard	implants.
Narrow	diameter	implants	(NDI)	have	been	classified	into	three	categories:	Category	1:	
Implants	with	a	diameter	of	<2.5	mm	(“Mini‐	implants”);	Category	2:	Implants	with	a	diam‐
eter	of	2.5	mm	to	<3.3	mm;	Category	3:	Implants	with	a	diameter	of	3.3	mm	to	3.5	mm.	
Mean	survival	rates	were	94.7	±	5%,	97.3	±	5%	and	97.7	±	2.3%	for	category	1,	2	and	3.
Tapered	versus	non‐tapered	implants	demonstrated	only	insignificant	differences	re‐
garding	clinical,	radiographic,	and	patient‐	reported	outcomes.	
The	intake	of	certain	selective	serotonin	reuptake	inhibitors	and	proton	pump	inhibi‐
tors	is	associated	with	a	statistically	significant	increased	implant	failure	rate.	The	in‐
take	of	bisphosphonates	related	to	the	treatment	of	osteoporosis	was	not	associated	
with	an	increased	implant	failure	rate.
Conclusions:	It	is	concluded	that	short	implants	(≤6	mm)	are	a	valid	option	in	situations	
of	reduced	bone	height	to	avoid	possible	morbidity	associated	with	augmentation	pro‐
cedures;	however,	 they	 reveal	 a	higher	variability	 and	 lower	predictability	 in	 survival	
rates.	Narrow	diameter	implants	with	diameters	of	2.5	mm	and	more	demonstrated	no	
difference	in	implant	survival	rates	compared	to	standard	diameter	implants.	In	contrast,	
it	is	concluded	that	narrow	diameter	implants	with	diameters	of	less	than	2.5	mm	exhib‐
ited	lower	survival	rates	compared	to	standard	diameter	implants.	It	is	further	concluded	
that	there	are	no	differences	between	tapered	versus	non‐tapered	dental	implants.
Certain	medications	such	as	selective	serotonin	reuptake	inhibitors	and	proton	pump	
inhibitors	showed	an	association	with	a	higher	implant	failure	rate.
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1  | INTRODUC TION
The	 objectives	 of	 Group	 1	 of	 the	 6th	 ITI	 Consensus	 Conference	
were	to	provide	statements	and	recommendations	for	clinicians	and	
researchers	related	to	short	implants	(≤6	mm),	narrow	diameter	im‐
plants	(≤3.5	mm),	implant	designs	(tapered	versus	non‐tapered),	and	
certain	medications	 on	 clinical,	 radiographic,	 and	 patient‐	reported	
outcomes	in	implant	dentistry.
For	Working	Group	1,	four	systematic	reviews	have	been	pre‐
pared	and	reviewed	before	the	Consensus	Conference.	Based	on	
the	 data	 and	 the	 meta‐	analysis	 of	 the	 individual,	 systematic	 re‐
views	and	basis	on	thorough	discussions	among	the	participants	of	
Group	1	and	among	the	entire	plenum	of	the	conference	consen‐
sus	 statements	 and	 clinical	 recommendations	were	 carefully	 for‐
mulated.	 In	 addition,	 recommendations	 for	 future	 research	were	
also	prepared	by	the	working	group.	The	four	systematic	reviews	
are	listed	below:
1.	Survival	rates	of	short	dental	implants	(≤6	mm)	compared	with	im‐
plants	longer	than	6	mm	in	posterior	jaw	areas:	A	meta‐analysis.	
Panos	Papaspyridakos,	Andre	De	Souza,	Konstantinos	Vazouras,	
Hadi	Gholami,	Sarah	Pagni,	Hans‐Peter	Weber
2.	Narrow	diameter	implants:	A	systematic	review	and	meta‐analysis
Eik	Schiegnitz,	Bilal	Al‐Nawas
3.	Systematic	review	of	clinical	and	patient‐reported	outcomes	fol‐
lowing	oral	rehabilitation	on	dental	implants	with	a	tapered	com‐
pared	to	a	non‐tapered	implant	design
Asbjørn	Jokstad,	Jeffrey	Ganeles
4.	Medication‐related	dental	implant	failure:	Systematic	review	and	
meta‐analysis
Vivianne	 Chappuis,	 Gustavo	 Avila‐Ortiz,	 Mauricio	 Araújo,	
Alberto	Monje
2  | SURVIVAL R ATES OF SHORT DENTAL 
IMPL ANTS (≤6 MM) COMPARED WITH 
IMPL ANTS LONGER THAN 6 MM IN 
POSTERIOR JAW ARE A S: A META- ANALYSIS
2.1 | Preamble
Short	 implants	have	been	proposed	as	an	alternative	to	eliminate	or	
reduce	 the	 need	 for	 vertical	 bone	 augmentation	 procedures,	which	
are	 often	 associated	 with	 additional	 costs,	 longer	 treatment	 time,	
increased	postoperative	morbidity,	and	greater	risk	for	complications.	
However,	the	long‐	term	efficacy	of	short	dental	implants	has	been	a	
topic	of	 controversy	 in	 the	dental	 implant	 literature.	Whereas	 some	
studies	reported	lower	survival	rates	for	short	compared	to	longer	im‐
plants,	other	reports,	including	a	number	of	systematic	reviews,	more	
recently	concluded	that	survival	rates	of	short	implants	are	similar	to	
longer	 implants	placed	 in	pre‐	existing	or	grafted	bone.	The	majority	
of	studies	does	not	include	direct	comparisons	of	the	performance	of	
short	and	longer	implants.	The	interpretation	of	the	literature	is	also	
complicated	by	 the	 fact	 that	authors	have	defined	“short	dental	 im‐
plants”	differently.	Some	have	considered	<10	mm	as	short,	whereas	
in	other	studies,	 short	 implants	were	8	mm	or	 less,	7	mm	or	 less,	or	
6	mm	or	less.
The	purpose	of	this	study	was	to	systematically	review	random‐
ized	controlled	clinical	trials	(RCTs)	reporting	on	long‐	term	survival	
as	well	as	complication	rates	of	short	implants	(≤6	mm)	versus	lon‐
ger	 implants	 (>6	mm)	 in	posterior	 jaw	areas	of	partially	edentulous	
patients.
The	main	goal	and	primary	outcome	of	this	systematic	review	and	
meta‐	analysis	was	to	compare	long‐	term	survival	rates	between	short	
implants	(≤6	mm)	and	longer	implants	(>6	mm)	in	posterior	jaw	areas.
Secondary	outcomes	were	as	follows:	
•	 Radiographic	bone	levels
•	 Prosthesis	survival
•	 Implant	complications
The	 present	 systematic	 review	 is	 based	 on	 10	 randomized	
clinical	trials	including	775	patients	(392	with	short	and	383	with	
longer	implants)	representing	a	total	of	1,290	implants	(637	short	
and	653	 longer	 implants).	The	follow‐	up	period	ranged	from	1	to	
5	years.
Sufficient	 data	were	 available	 to	 perform	 a	meta‐	analysis	 of	
the	 primary	 outcome	 (implant	 survival).	 Only	 descriptive	 analy‐
ses	were	possible	for	the	secondary	outcomes	radiographic	bone	
levels,	 prosthesis	 survival,	 and	 biologic	 complication	 rates	 for	
implants.
When	interpreting	the	results,	it	is	important	to	realize	that	only	
three	of	the	10	studies	evaluated	the	performance	of	short	and	lon‐
ger	implants	in	a	randomized	manner	in	sites	allowing	the	placement	
of	 both	 types	 of	 implants.	 The	other	 seven	 studies	 compared	 the	
use	 of	 short	 implants	 to	 longer	 implants	 in	 conjunction	with	 aug‐
mentation	procedures.	In	other	words,	these	seven	studies	compare	
different	treatment	approaches	and	not	necessarily	implant	lengths	
per	se.	This	difference	needs	to	be	kept	in	mind	when	comparing	the	
results	of	these	studies.
K E Y W O R D S
biological	complications,	clinical	decision‐making,	dental	implants,	drug,	endosseous	implant,	
epidemiology,	failure,	humans,	medication,	meta‐analysis,	narrow	diameter,	osteotomy,	
randomized	controlled	trials,	review,	short	dental	implants,	small	dental	implants,	survival
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2.2 | Consensus statements
2.2.1 | Consensus statement 1
Short	 implants	 (≤6	mm)	 exhibit	 similar	 survival	 rates	 compared	 to	
longer	implants	(>6	mm)	after	periods	of	1–5	years	in	function.	The	
mean	survival	rate	was	96%	(range:	86.7%–100%)	for	short	implants,	
and	98%	(range	95%–100%)	for	longer	implants.	The	meta‐	analysis	
showed	a	risk	ratio	of	1.29	(95%	CI:	0.67,	2.50,	P = 0.45) for failure 
when	short	implants	were	used.
This	statement	is	based	on	a	meta‐	analysis	of	10	RCTs	including	
775	patients	(392	patients	with	short,	383	with	longer	implants)	and	
1,290	implants	(637	short,	653	longer	implants).
2.2.2 | Consensus statement 2
Time	in	function	may	reduce	the	survival	rate	of	short	implants	more	
than	that	of	longer	implants.
This	statement	is	based	on	one	RCT	with	a	follow‐	up	of	5	years	
including	45	patients	and	60	implants	(30	short,	30	longer).	This	is	
additionally	 confirmed	 by	 a	 recently	 published	 RCT	with	 a	 5‐	year	
patient	follow‐	up	that	could	not	be	included	as	it	was	published	after	
the	cut‐	off	date	for	inclusion	in	the	systematic	review.
2.2.3 | Consensus statement 3
Short	 and	 longer	 implants	 present	 similar	 amounts	 of	 radio‐
graphic	 interproximal	 bone	 level	 changes.	 Following	 a	 period	 of	
1–5	years,	the	radiographic	interproximal	bone	level	changes	for	
the	short	implants	ranged	from	+0.06	to	−1.22	mm,	whereas	the	
corresponding	values	for	the	 longer	 implants	ranged	from	+0.02	
to	−1.54	mm.
This	statement	is	based	on	10	RCTs	including	775	patients	(392	
patients	with	short,	383	with	 longer	 implants)	and	1,290	 implants	
(637	short,	653	longer	implants).
2.2.4 | Consensus statement 4
The	rate	of	surgical	and	postsurgical	complications	is	higher	in	the	
longer	implant	group	(mean:	32.8%;	range:	0–90%)	compared	to	the	
short	 implants	 (mean:	6.8%;	 range:	0–26%).1	 In	 the	 longer	 implant	
group,	 the	 majority	 of	 complications	 were	 associated	 with	 bone	
grafting	procedures.2
2.2.5 | Consensus statement 5
Prosthesis	survival	for	short	and	longer	implants	following	a	period	
of	1–5	years	is	similarly	high.	The	mean	prosthesis	survival	rate	was	
98.6%	(range:	90%–100%)	for	the	short	implants,	and	99.5%	(range:	
95%–100%)	for	the	longer	implants.
This	statement	is	based	on	nine	RCTs	including	625	patients	(317	
patients	with	short	and	308	with	longer	implants).
2.3 | Clinical recommendations
2.3.1 | What are the current indications for short 
implants?
Short	implants	are	a	valid	option	in	situations	of	reduced	bone	height	
when	it	is	important	to	avoid	possible	morbidity	associated	with	aug‐
mentation	procedures	or	to	reduce	treatment	time.	They	may	also	be	
preferred	when	the	possibility	of	damage	to	adjacent	structures	can	
be	significantly	reduced.	Adjacent	structures	include	maxillary	sinuses,	
blood	vessels	and	nerves,	tooth	structures	and	existing	implants.
2.3.2 | Should longer implants be the first choice?
The	selection	of	 the	 length	of	an	 implant	depends	on	site‐	specific	
local	 anatomical	 and	 patient	 conditions.	 When	 sufficient	 bone	
height	exists,	 implants	 longer	 than	6	mm	are	preferred	when	they	
can	be	placed	without	increasing	surgical	risk.
2.3.3 | Can short implants be immediately loaded?
The	 loading	 times	 for	 short	 implants	 reported	 in	 the	 litera‐
ture	 ranged	 from	 6	weeks	 to	 6	months.	 At	 the	 present	 time,	 no	
evidence‐	based	 recommendation	 can	 be	 made	 for	 immediate	
loading.
2.3.3 | Does implant diameter affect the survival of 
short implants?
Based	on	the	findings	from	the	studies	included	in	this	review,	short	
implants	with	a	diameter	of	4	mm	or	greater	should	be	used.
2.3.4 | Should adjacent short implants be splinted?
Based	on	the	findings	from	the	studies	included	in	this	review,	the	
clinical	recommendation	is	made	to	splint	restorations	involving	ad‐
jacent	short	implants.
2.3.5 | What are the occlusal considerations for 
restorations on short implants?
Although	the	reviewed	literature	does	not	give	specific	recommen‐
dations	 regarding	 occlusion,	 a	 greater	 risk	 of	 occlusal	 overload	 of	
short	 implants	 has	 to	 be	 considered.	Caution	 is	 especially	 advised	
when	 indicating	 short	 implants	 in	 patients	 presenting	 with	 single	
missing	molars	 and/or	 parafunctional	 habits.	 Changes	 in	 occlusion	
should	be	assessed	and	adjusted	as	necessary	during	regular	main‐
tenance	visits.
1This	statement	is	based	on	eight	RCTs	including	590	patients	(298	patients	with	short,	
292	with	longer	implants)	having	1,022	implants	(500	short,	522	longer	implants).
2This	statement	is	based	on	six	RCTs	including	305	patients	(134	patients	with	short	and	
171	with	longer	implants)	and	confirms	previous	consensus	reports.
     |  73JUNG et al.
2.4 | Recommendations for future research
•	 Prospective	 long‐term	 clinical	 studies	 on	 the	 performance	 of	
short	implants	(>5	years)
•	 Randomized	 clinical	 trials	 comparing	 short	 and	 longer	 im‐
plants	 in	 intact	 bone	 sites	 without	 the	 need	 for	 vertical	 bone	
augmentation.
•	 RCTs	 or	 long‐term	 controlled	 clinical	 studies	 on	 the	 effect	 of	
splinting
•	 Studies	on	optimal	implant	design	for	short	implants
3  | NARROW DIAMETER IMPL ANTS: A 
SYSTEMATIC RE VIE W AND META- ANALYSIS
3.1 | Preamble
Narrow	diameter	implants	(NDI)	are	used	in	clinical	situations	includ‐
ing	narrow	bony	ridges	as	an	alternative	to	bone	augmentation	pro‐
cedures	and	in	sites	with	reduced	interdental	gap	width.	The	aim	of	
the	systematic	review	was	to	assess	the	survival	rates	of	NDI	made	
from	titanium	or	titanium	alloy	and	to	provide	recommendations	and	
guidelines	for	the	application	of	NDI.
There	is	a	need	for	clarity	and	standardization	in	the	description	
of	the	diameter	of	an	implant.	For	the	purpose	of	this	study,	the	max‐
imal	endosseous	implant	diameter	has	been	used,	including	implant	
threads,	as	provided	by	the	implant	manufacturer.	The	available	lit‐
erature	describes	the	use	of	different	types	of	NDI,	but	it	appears	
generally	accepted	that	a	NDI	is	one	with	a	diameter	of	≤3.5	mm.
Since	the	previous	classification	of	NDI	(Klein,	Schiegnitz,	&	Al‐	
Nawas,	 2014),	 there	 have	 been	 new	 developments	 in	 the	 field	 of	
NDI	and	therefore,	the	following	modification	to	this	classification	
is	proposed:	
Category	1:	Implants	with	a	diameter	of	<2.5	mm	(“Mini‐implants”)
Category	2:	Implants	with	a	diameter	of	2.5	mm	to	<3.3	mm
Category	3:	Implants	with	a	diameter	of	3.3	mm	to	3.5	mm
At	the	present	time,	most	implants	of	<2.5	mm	diameter	are	one‐	
piece	 implants.	One‐	piece	 implants	with	 a	 diameter	 of	 >3.0	mm	are	
rarely	described.
From	5,845	records	retrieved	initially,	72	studies	were	included	
in	the	qualitative	analysis	and	16	studies	in	the	quantitative	anal‐
ysis.	Quality	assessment	of	the	included	literature	showed	consid‐
erable	 variation,	with	 a	 high	 risk	 of	 bias.	 It	 should	 be	 noted	 that	
important	aspects	 relating	 to	 clinical	outcomes	are	not	 reported:	
There	are	no	data	on	patient‐	reported	outcome	measures,	loading	
protocols,	biological	or	technical	complications,	all	of	which	could	
impact	on	the	actual	clinical	performance	and	longevity	of	the	pro‐
vided	treatment.
It	is	important	to	note	that	there	are	no	studies	comparing	NDI	
without	bone	augmentation	procedures	to	SDI	with	bone	augmen‐
tation	procedures.
3.2 | Consensus statements
3.2.1 | Consensus statement 1
Mean	survival	 rate	of	Category	1	 implants	was	94.5%	±	5%	 (Range	
80%–100%)	after	observation	periods	of	12–78	months.	The	most	fre‐
quently	described	applications	of	these	implants	were	for	transitional	
restorations,	overdentures,	and	single	anterior	tooth	replacement.
This	statement	is	based	on	20	clinical	trials	(eight	RS,	10	PS,	and	
two	RCTs)	with	1,220	patients	and	5,367	implants.	The	majority	of	
the	included	papers	exhibited	a	high	risk	of	bias.
3.2.2 | Consensus statement 2
Mean	 survival	 rates	of	Category	2	 implants	were	97.3%	±	4%	 (Range	
80.5%–100%)	after	observation	periods	of	12–63	months.	The	most	fre‐
quently	described	application	was	for	single	anterior	tooth	replacement.
This	statement	is	based	on	21	clinical	trials	(10	RS,	9	PS,	and	2	
RCTs)	with	883	patients	and	1,207	implants.	The	majority	of	the	in‐
cluded	papers	exhibited	a	high	risk	of	bias.
Compared	to	SDI,	Category	2	NDI	exhibit	comparable	survival	
rates	in	meta‐	analysis	([OR],	1.06;	[CI],	0.31–3.61).	This	statement	is	
based	on	four	clinical	trials	(2	RS,	1	PS,	and	1	RCT).	The	majority	of	
the	included	papers	exhibited	a	high	risk	of	bias.
3.2.3 | Consensus statement 3
Mean	survival	rates	of	Category	3	implants	were	97.7%	±	2%	(Range	
91%–100%)	after	observation	periods	of	12–109	months.	The	ap‐
plications	of	these	implants	were	not	always	precisely	defined,	but	
also	included	the	replacement	of	posterior	teeth	in	either	arch.
This	statement	is	based	on	35	clinical	trials	(17	RS,	12	PS,	and	six	
RCT)	with	3,842	patients	and	5,612	 implants.	The	majority	of	 the	
included	papers	exhibited	a	high	risk	of	bias.
Compared	to	SDI,	Category	3	NDI	exhibit	comparable	survival	
rates	in	meta‐	analysis	([OR],	1.19;	[CI],	0.83–1.70).	This	statement	is	
based	on	10	clinical	trials	(eight	RS,	and	two	RCT).	The	majority	of	
the	included	papers	exhibited	a	high	risk	of	bias.
3.2.4 | Consensus statement 4
There	 is	 insufficient	 evidence	 on	 the	 success	 rates	 for	 all	 NDIs.	
Clinical	 parameters	 and	 treatment	 protocols	 are	 often	 not	 suffi‐
ciently	described	and	no	controlled	comparative	 long‐	term	studies	
are	available,	resulting	in	a	high	risk	of	bias.
3.3 | Clinical recommendations
3.3.1 | What are the potential advantages of using 
NDI?
•	 NDI	should	be	considered	when	it	is	important	to	ensure	mainte‐
nance	of	adequate	tooth‐implant	and	implant‐implant	distances	in	
74  |     JUNG et al.
sites	with	reduced	mesio‐distal	width.
•	 The	use	of	NDI	can	be	considered	to	reduce	the	need	or	complex‐
ity	of	lateral	bone	augmentation	procedures	to	reduce	morbidity.
•	 The	use	of	NDI	may	allow	simultaneous	rather	than	staged	bone	
augmentation	procedures.
•	 The	use	of	NDI	may	provide	increased	prosthetic	flexibility	in	cer‐
tain	clinical	situations.
3.3.2 | What are the potential disadvantages of 
using NDI?
Biological
•	 One‐piece	NDI	with	ball	attachments	might	be	difficult	to	manage	
at	the	onset	of	dependency.
•	 The	use	of	NDI	may	compromise	optimal	prosthetic	designs	al‐
lowing	the	maintenance	of	peri‐implant	tissue	health.
Mechanical
•	 Reducing	implant	diameter	brings	an	increased	risk	of	implant	or	
component	fracture.
•	 Caution	is	recommended	for	the	use	of	NDI	in	patients	with	para‐
functional	habits	and	malocclusions.
3.3.3 | Should NDI be splinted?
Given	 the	 reduced	 implant	 strength	 and	 bone	 contact	 offered	 by	
NDI,	 it	may	be	advisable	to	use	splinted	restorations	based	on	the	
individual	clinical	situation.
3.3.4 | What are the indications for each 
classification of NDI?
Category	1	implants	can	be	considered	for:	
o	 Support	of	definitive	complete	mandibular	overdentures
o	 Support	of	interim	prostheses,	both	fixed	and	removable
Category	2	implants	can	be	considered	for:	
o	 Support	of	definitive	complete	mandibular	overdentures
o	 Support	of	single	tooth	replacement	in	the	anterior	zone	with	
narrow	interdental	width	(maxillary	lateral	incisors	and	single	
mandibular	incisors)
Category	3	implants	can	be	considered	for:	
o	 Support	of	definitive	complete	overdentures
o	 Support	of	single	tooth	replacement	in	sites	with	reduced	in‐
terdental	and/or	buccal‐lingual	width
o	 Support	of	multiple	unit	restorations
Personalized	informed	consent	should	include	the	possibility	of	more	
technical	and	biological	complications.
3.4 | Recommendations for future research
•	 Future	studies	should	compare	the	success	and	patient‐reported	
outcome	measures	 between	NDI	without	 augmentation	 proce‐
dure	and	SDI	with	an	augmentation	procedure.
•	 Future	 studies	 should	 document	 long‐term	 results	 of	 potential	
technical	and	biological	complications
•	 Future	 studies	 should	 compare	 new	 materials	 and	 implant	
designs.
•	 Future	 studies	 should	 investigate	 the	 aesthetic	 outcome	 of	
NDI.
4  | SYSTEMATIC RE VIE W OF CLINIC AL 
AND PATIENT-  REPORTED OUTCOMES 
FOLLOWING OR AL REHABILITATION ON 
DENTAL IMPL ANTS WITH A TAPERED 
COMPARED TO A NON-TAPERED IMPL ANT 
DESIGN
4.1 | Preamble
Approximately	50%	of	all	implants	on	the	market	are	tapered.	In	this	
systematic	 review,	a	 tapered	 implant	 is	 recognized	as	a	 cylindrical	
implant	where	the	endosseous	part	narrows	in	diameter	toward	the	
apex.	The	rationale	for	using	this	 implant	design	 is	 to	 improve	pri‐
mary	stability	and	subsequent	treatment	success.
The	present	systematic	review	evaluated	the	scientific	evidence	
related	to	 implant	survival	and	success	to	address	the	question:	 In	
patients	 with	 dental	 implant	 restorations,	 do	 tapered	 compared	
to	 non‐tapered	 implants	 demonstrate	 similar	 clinical	 and	 patient‐	
reported	outcomes?
Twenty‐	nine	 articles	 were	 identified	 of	 which	 three	 RCTs	 re‐
ported	outcomes	at	3	years.	The	three	RCTs	described	the	results	of	
245	patients	with	388	implants	at	three	years	and	reported	clinically	
insignificant	 differences.	 The	 three	 RCTs	 each	 reported	 different	
clinical	outcomes	and	the	data	were	not	comparable.	None	reported	
patient‐	reported	 outcomes	 or	maintenance	 needs.	 All	 three	 RCTs	
have	a	moderate	risk	of	bias.	Meta‐	analyses	were	not	conducted.
4.2 | Consensus statements
4.2.1 | Consensus statement 1
The	 evidence	 shows	 that	 both	 tapered	 and	 non‐tapered	 implants	
demonstrate	 satisfactory	 performance	 with	 respect	 to	 marginal	
bone	 levels	at	3	years.	This	statement	 is	based	on	the	evidence	of	
three	RCTs,	(245	patients	with	388	implants).
4.2.2 | Consensus statement 2
There	is	currently	insufficient	evidence	to	conclude	if	tapered	com‐
pared	 with	 non‐tapered	 implants	 demonstrate	 similar	 clinical	 and	
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patient‐	reported	outcomes.	This	statement	is	based	on	the	evidence	
from	three	RCTs,	(245	patients	with	388	implants).
4.3 | Clinical recommendations
4.3.1 | Is there a recommendation for any specific 
implant design with regard to taper?
Based	 on	 Consensus	 statements	 1	 and	 2,	 both	 tapered	 and	
non‐tapered	 implants	 can	 be	 used	 according	 to	 the	 operator’s	
preference.
4.3.2 | Are there particular clinical situations in which 
any specific implant design with regard to taper is 
preferred?
Tapered	implants	can	be	considered	in	clinical	situations	to	avoid	in‐
juring	anatomical	structures	or	causing	apical	fenestrations.
Appropriate	professional	judgment	and	clinical	decision‐	making	
must	 include	 a	 comprehensive	 diagnosis	 of	 the	 patient’s	 jawbone	
anatomy,	bone	quality	and	quantity,	and	osteotomy	protocol.
4.3.3 | Is utilizing a tapered implant an effective 
strategy to increase insertion torque?
In	 situations	where	 increased	 insertion	 torque	 is	 desired,	 tapered	
implants	may	be	considered.	The	shape	of	the	dental	implant	is	only	
one	contributing	 factor	 to	achieve	high	 insertion	torque;	however,	
the	 clinical	 significance	 of	 implant	 shape	 on	 long‐	term	 results	 is	
unclear.
4.4 | Recommendations for future research
•	 Clinically	validate	a	nomenclature	and	classification	system	to	de‐
scribe	and	compare	different	configurations	of	“tapered”	implants	
(Figure	1).
•	 Clinical	 studies	 that	 aim	 to	 compare	 tapered	 versus	 non‐tapered	
implant	designs	should	include	details	of	bone	quality	and	quantity,	
the	osteotomy	preparation	protocols,	(osteotomy	shape,	degree	of	
under	sizing,	method	of	osteotomy	(twist	drill,	piezo,	condensation,	
etc.)).
•	 Establish	 whether	 insertion	 torque	 and	 resonance	 frequency	
analysis	are	valid	indicators	of	the	risk	of	micromotion	as	a	func‐
tion	of	the	implant	design.
5  | MEDIC ATION- REL ATED DENTAL 
IMPL ANT FAILURE: A SYSTEMATIC RE VIE W 
AND META- ANALYSIS
5.1 | Preamble
Current	global	trends	indicate	that	the	general	population’s	expec‐
tancy	of	 life	 is	 increasing	worldwide.	 These	demographic	 changes	
have	been	associated	with	an	increase	in	the	intake	of	medications	
for	 the	 treatment	of	highly	prevalent	medical	 conditions.	Some	of	
these	medications	may	influence	tissue	metabolism	and,	therefore,	
the	 outcomes	 of	 implant	 therapy	 in	 certain	 cohorts.	 Interestingly,	
the	 impact	of	medication	 that	may	particularly	alter	bone	homeo‐
stasis	upon	implant	therapy	outcomes	has	not	been	systematically	
explored.
The	main	goal	of	this	systematic	review	was	to	assess	the	asso‐
ciation	of	 implant	 failure	 rate	 as	 the	primary	outcome	with	 intake	
of	oral	or	parenteral	medications	that	may	affect	bone	metabolism.
Secondary	outcomes	were:	
•	 Timing	of	implant	failure.
•	 Marginal	bone	loss.
•	 Biological	and	Mechanical/Technical	complications.
The	present	systematic	review	includes	17	investigations,	one	CCT	
had	to	be	excluded	due	to	missing	reports	on	 implant	 failures	rates.	
The	16	remaining	studies	consisted	of	three	RCTs,	one	PC	and	12	RC	
including	a	total	of	4,827	patients	with	13,247	implants.
A	 total	of	 five	different	categories	of	medications	were	 identi‐
fied	 upon	 completion	 of	 the	 systematic	 search:	 nonsteroidal	 anti‐	
inflammatory	 medication	 (NSAIDs),	 antihypertensive	 medication	
(AHTNs),	 selective	 serotonin	 reuptake	 inhibitors	 (SSRIs),	 proton	
pump	 inhibitors	 (PPIs),	 and	 bisphosphonates	 (BPs).	 Sufficient	 data	
were	available	 to	perform	meta‐	analyses	of	 the	primary	outcomes	
for	SSRIs,	PPIs,	and	BPs.	The	heterogeneity	of	the	study	design	and	
methodology	in	the	selected	studies	did	not	allow	for	meta‐	analyses	
for	 any	 of	 the	 secondary	 outcomes.	 Limitation	 of	 this	 systematic	
F IGURE  1 Different	types	of	configurations	and	geometrie	for	tapered	implants	available	on	the	dental	market
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review	is	related	to	differences	in	study	design	and	medication	reg‐
imens,	in	addition	to	confounding	factors,	such	as	comorbidity	and	
polypharmacy	 among	others	 reported	 in	 the	 literature.	Therefore,	
the	 findings	 of	 this	 systematic	 review	 should	 be	 interpreted	with	
caution.
5.2 | Consensus statements
5.2.1 | Consensus statement 1: General Statement
Limited	evidence	on	the	effect	of	 long‐	and	short‐	term	medication	
intake	on	dental	implant	therapy	outcomes	indicates	that	there	may	
be	an	association	between	implant	failure	rate	and	the	intake	of	cer‐
tain	medications	that	influence	bone	metabolism.
5.2.2 | Consensus statement 2: nonsteroidal anti‐ 
inflammatory drugs (NSAIDs)
The	 association	 between	 nonsteroidal	 anti‐	inflammatory	 drug	
(NSAID)	intake	and	implant	failure	rate	is	unclear.
This	statement	is	based	on	the	analysis	of	five	studies	(i.e.,	three	
RCTs,	including	a	total	of	191	patients,	and	two	retrospective	cohort	
studies,	 including	a	total	of	81	patients)	that	revealed	marked	het‐
erogeneity	of	 the	pharmacological	 regimen	 in	 the	selected	studies	
and	a	majority	of	studies	reporting	no	implant	failures	in	either	the	
test	or	control	groups,	or	both	groups.
i.e.,	Ibuprofen,	Flurbiprofen,	Celecoxib,	Acetylsalicylic,	Rofecoxib,	
Nabumetone,	Naproxen,	Etodolac	and	others.
5.2.3 | Consensus statement 3: antihypertensive 
medication (AHTNs)
The	association	between	the	long‐	term	intake	of	certain	AHTNs	and	
implant	failure	rate	is	unclear.
This	statement	is	based	on	very	limited	available	evidence	of	one	
retrospective	study	including	728	patients.	Noteworthy,	AHTNs	ex‐
hibited	a	lower	implant	failure	rate	compared	to	the	control	popula‐
tion	not	taking	AHTNs	in	this	study.
i.e.,	 Beta‐	blockers,	 Thiazide	 diuretics,	 Angiotensin‐	converting	
enzyme	inhibitors,	Angiotensin	II	receptor	blockers	and	others.
5.2.4 | Consensus statement 4: selective serotonin 
reuptake inhibitors (SSRIs)
The	intake	of	certain	SSRIs	is	associated	with	a	statistically	signifi‐
cant	increased	implant	failure	rate.
This	statement	is	based	on	the	quantitative	analysis	of	two	ret‐
rospective	 cohort	 studies	 including	 a	 total	 of	 790	 patients,	which	
suggested	 that	 implant	 failure	 rate	 was	 higher	 in	 subjects	 taking	
SSRIs	as	compared	to	a	control	population	(Odd	ratio:	2.92;	average	
difference:	7.48%,	C.I.	 [95%]	=	6.96–8.00	with	a	p	<	0.01,	between	
36	and	90	months	of	follow‐	up).
i.e.,	 Citalopram,	 Dapoxetine,	 Escitalopram,	 Fluoxetine,	
Fluvoxamine,	 Indalpine,	 Paroxetine,	 Sertraline,	 Venlafaxine	 and	
Zimeline	and	others.
5.2.5 | Consensus statement 5: proton pump 
inhibitors (PPIs)
The	 intake	 of	 PPIs	 is	 associated	with	 a	 statistically	 significant	 in‐
creased	implant	failure	rate.
This	statement	is	based	on	the	quantitative	analysis	of	two	ret‐
rospective	cohort	studies	including	a	total	of	1,798	patients,	which	
suggested	that	implant	failure	rate	was	higher	in	subjects	taking	PPIs	
as	compared	to	a	control	population	(Odds	ratio:	2.02;	average	dif‐
ference:	4.29%,	C.I.	[95%]	=	3.81–4.77	with	a	p	<	0.01,	between	16	
and	94	months	of	follow‐	up).
i.e.,	Omeprazole,	Lansoprazole,	Pantoprazole,	Dexlansoprazole,	
Esomeprazole,	Rabeprazole	and	others.
5.2.6 | Consensus statement 6: bisphosphonates 
(BPs) related to osteoporosis
The	intake	of	BPs	related	to	the	treatment	of	osteoporosis	was	not	
associated	with	an	increased	implant	failure	rate.
This	 statement	 is	 based	 on	 the	 quantitative	 analysis	 of	 six	
cohort	 studies	 (i.e.,	 five	 retrospective	on	oral	BPs	and	one	pro‐
spective	 using	 intravenous	 BPs	 including	 a	 total	 of	 1,239	 pa‐
tients),	 which	 suggested	 that	 implant	 failure	 rate	was	 higher	 in	
subjects	 taking	 BPs	 as	 compared	 to	 a	 control	 population	 (aver‐
age	 difference:	 −0.13%,	 C.I.	 [95%]	=	−0.3	 to	 0.05,	 between	 12	
and	66	months	of	 follow‐	up).	Caution	should	be	 taken	when	 in‐
terpreting	 these	 data	 due	 to	 the	 inherent	 risks	 associated	with	
the	occurrence	of	medication‐	induced	osteonecrosis	 in	patients	
taking	BPs.
The	 effect	 of	 BP	 on	 implant	 outcomes	 in	 patients	 undergoing	
treatment	 of	 neoplastic	 diseases	 therapy	 was	 not	 evaluated,	 be‐
cause	implant	therapy	is	usually	contraindicated	in	this	population.
i.e.,	Risedronate,	Ibandronate,	Alendronate,	Zoledronic	acid	and	
others.
5.3 | Clinical recommendations
5.3.1 | What are the implications of the increasing 
intake of medication by the general population in 
daily practice?
Clinicians	 and	 patients	 considering	 implant	 therapy	 should	 be	
aware	 of	 possible	 medication‐	related	 implant	 failures.	 Hence,	 a	
comprehensive	 assessment	 and	 understanding	 of	 the	 patient’s	
medical	background	and	current	medications,	as	well	as	a	person‐
alized	 informed	 consent,	 should	 be	 considered	 integral	 compo‐
nents	 of	 all	 phases	 of	 contemporary	 implant	 therapy	 (initial	 and	
supportive	therapy).
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5.3.2 | What considerations should be taken in daily 
clinical practice pertaining medication intake‐ related 
implant failure?
Clinicians	 should	 consider	 the	 association	 between	 increased	 im‐
plant	failure	rate	and	the	intake	of	proton	pump	inhibitors	(PPIs)	or	
selective	 serotonin	 reuptake	 inhibitors	 (SSRIs)	 in	 their	 routine	 risk	
assessment	as	part	of	comprehensive	implant	therapy.
Clinicians	 should	 proceed	 with	 caution	 when	 implant	 therapy	
is	 considered	 in	 patients	 taking	 bisphosphonates	 (BPs)	 related	 to	
osteoporosis.
Standard	 implant	 therapy	 is	 contraindicated	 in	patients	 receiv‐
ing	high‐	dose	bisphosphonates	(BPs)	for	the	treatment	of	neoplastic	
diseases.
5.4 | Recommendations for future research
•	 To	elucidate	potential	mechanisms	of	 action	 that	would	explain	
the	effect	of	certain	medications	on	bone	and	soft	tissue	homeo‐
stasis	 around	 implants	 exhibiting	 different	 macro‐	 and	 micro‐
scopic	features	via	the	conduction	of	in vivo	preclinical	studies.
•	 To	 investigate	 potential	 cause–effect	 relationships	 between	 the	
intake	 of	 certain	 medications	 and	 implant	 outcomes	 through	
prospective	 clinical	 trials	 evaluating	 clinical,	 radiographic,	micro‐
biological,	histological,	PROMs,	and	other	parameters.	This	will	ex‐
pand	our	knowledge	and	increase	the	success	of	implant	therapy..
•	 To	evaluate	the	effect	of	confounders,	such	as	the	disease	itself,	co‐
morbidities,	behavioral	aspects,	and	polypharmacy,	on	implant	ther‐
apy	outcomes	in	prospective	clinical	trials	including	target	populations.
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